AlidaBio
Alida Biosciences is revolutionizing epigenomics and leading the way in next-generation RNA modification analysis, empowering breakthroughs in research, therapeutics, and diagnostics. Founded in 2020, Alida develops groundbreaking products that simplify bioinformatics, enabling concurrent analysis of multiple RNA modifications with relative quantification. Our solutions utilize RNA inputs suitable for clinically relevant samples, offering unparalleled workflow efficiency and accessibility. AlidaBio is proudly backed by Genoa Ventures, FusionX Ventures, and Vertical Venture Partners, alongside ongoing support from multiple SBIR grants from the National Human Genome Research Institute (NHGRI).
Content by AlidaBio
|3 min read
AlidaBio Launches EpiPlex™ Platform to Advance Epitranscriptomic Research
EpiPlex is first platform to offer multitarget, quantitative analysis of RNA modifications to provide comprehensive detection and characterization of the epitranscriptomePage 1 of 1




